During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...
CytoDyn (CYDY) announced that breast cancer specialist and medical oncologist, Milana V. Dolezal, MD, MSci, is presenting a ...
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...
High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...
BioNTech (BNTX) and Bristol Myers Squibb Company (BM) announced the first interim data from a global randomized Phase 2 trial evaluating pumitamig, an investigational bispecific antibody targeting ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cellsRemarkably ...
In 2024, based on the COMPASSION-15 study results, cadonilimab in combination with chemotherapy was approved in China for the first-line treatment of gastric cancer, demonstrating benefit across all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback